Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease. (February 2023)

• Record Type: Journal Article
• Authors: Carra-Dallière, Clarisse; Rollot, Fabien; Deschamps, Romain; Ciron, Jonathan; Vukusic, Sandra; Audoin, Bertrand; Ruet, Aurélie; Maillart, Elisabeth; Papeix, Caroline; Zephir, Hélène; Laplaud, David; Cohen, Mikael; Bourre, Bertrand; El-Bahi, Illiasse; Labauge, Pierre; Casey, Romain; Ayrignac, Xavier; Marignier, Romain
• Is Part Of: Multiple sclerosis. Volume 29:Number 2(2023)
• Page Start: 270
• Page End: 276
• Publication Date: 2023-02
• Subjects: MOGAD -- pregnancy -- postpartum -- relapse rate; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585221134214
• Languages: English
• ISSNs: 1352-4585

Abstract

Background and objective: Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) frequently initiates during childbearing years. This study investigated the impact of pregnancy and post-partum on MOGAD activity. Methods: Retrospective analysis of clinical and demographic data from a multicenter French cohort of adult patients with MOGAD. All adult female patients who had a pregnancy after disease onset or in the year before disease onset were included. The annualized relapse rate was evaluated in patients who had a pregnancy after disease onset, to evaluate the impact of pregnancy and post-partum on MOGAD course. Results: Twenty-five informative pregnancies after disease onset were identified. No relapse was recorded during these pregnancies and only three relapses occurred during the first 3 months post-partum. The annualized relapse rate decreased from 0.67 (95% confidence interval: 0.40–1.10) during the pre-pregnancy period to 0 (95% confidence interval: 0–0.21) during pregnancy and to 0.22 (95% confidence interval: 0.09–0.53) during the first year post-partum. Among 144 female patients in their childbearing age recorded in the database, 18 (12.5%) reported their first symptoms during pregnancy or in the 12 months post-partum. Discussion: Our study suggests a marked reduction of MOGAD relapse rate during pregnancy and the post-partum period. Prospective studies on the role of pregnancy and delivery in MOGAD course are needed.